Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership

- Zealand Pharma raises $1 billion to focus on its amylin analog for weight loss.
- The company aims to advance the drug into Phase 3 clinical trials.
- Zealand is also seeking a partner to support the development and commercialization of the drug.
- The raise is part of the growing interest in amylin as a target for weight loss treatments.
- Obesity is a significant health concern with severe consequences, including increased risk of chronic diseases.